Terms: = Liver cancer AND uPA AND Prognosis
35 results:
1. TIF1γ and SMAD4 regulation in colorectal cancer: impact on cell proliferation and liver metastasis.
Wu Y; Yu B; Ai X; Zhang W; Chen W; Laurence A; Zhang M; Chen Q; Shao Y; Zhang B
Biol Chem; 2024 Apr; 405(4):241-256. PubMed ID: 38270141
[TBL] [Abstract] [Full Text] [Related]
2. circPSD3 is a promising inhibitor of upa system to inhibit vascular invasion and metastasis in hepatocellular carcinoma.
Xu L; Wang P; Li L; Li L; Huang Y; Zhang Y; Zheng X; Yi P; Zhang M; Xu M
Mol Cancer; 2023 Oct; 22(1):174. PubMed ID: 37884951
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic role of urokinase plasminogen activator in hepatocellular carcinoma: A protocol for systematic review and meta analysis.
Tao P; Gao L; Li H; Wang B; Li X; Zhang Y; Chen H
Medicine (Baltimore); 2020 Dec; 99(52):e23841. PubMed ID: 33350772
[TBL] [Abstract] [Full Text] [Related]
4. Elevated levels of serum urokinase plasminogen activator predict poor prognosis in hepatocellular carcinoma after resection.
Tsai MC; Yen YH; Chang KC; Hung CH; Chen CH; Lin MT; Hu TH
BMC Cancer; 2019 Dec; 19(1):1169. PubMed ID: 31791275
[TBL] [Abstract] [Full Text] [Related]
5. Plasminogen Receptors in Human Malignancies: Effects on prognosis and Feasibility as Targets for Drug Development.
Gonias SL; Zampieri C
Curr Drug Targets; 2020; 21(7):647-656. PubMed ID: 31755385
[TBL] [Abstract] [Full Text] [Related]
6. TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis.
Huang HL; Liu YM; Sung TY; Huang TC; Cheng YW; Liou JP; Pan SL
Theranostics; 2019; 9(22):6676-6689. PubMed ID: 31588243
[TBL] [Abstract] [Full Text] [Related]
7. Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via upa- and RB/E2F1-related mechanisms.
Jin Y; Liang ZY; Zhou WX; Zhou L
Hepatol Int; 2019 Mar; 13(2):180-189. PubMed ID: 30600477
[TBL] [Abstract] [Full Text] [Related]
8. Evaluation of the Inhibitory Effects of Genipin on the Fluoxetine-Induced Invasive and Metastatic Model in Human HepG2 Cells.
Tian YS; Chen KC; Zulkefli ND; Maner RS; Hsieh CL
Molecules; 2018 Dec; 23(12):. PubMed ID: 30558243
[TBL] [Abstract] [Full Text] [Related]
9. Ruscogenin suppressed the hepatocellular carcinoma metastasis via PI3K/Akt/mTOR signaling pathway.
Hua H; Zhu Y; Song YH
Biomed Pharmacother; 2018 May; 101():115-122. PubMed ID: 29477471
[TBL] [Abstract] [Full Text] [Related]
10. Up-Regulation of PAI-1 and Down-Regulation of upa Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine.
Wang X; Wang N; Li H; Liu M; Cao F; Yu X; Zhang J; Tan Y; Xiang L; Feng Y
Int J Mol Sci; 2016 Apr; 17(4):577. PubMed ID: 27092498
[TBL] [Abstract] [Full Text] [Related]
11. The significance of Notch1 compared with Notch3 in high metastasis and poor overall survival in hepatocellular carcinoma.
Zhou L; Zhang N; Song W; You N; Li Q; Sun W; Zhang Y; Wang D; Dou K
PLoS One; 2013; 8(2):e57382. PubMed ID: 23468978
[TBL] [Abstract] [Full Text] [Related]
12. Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascade.
Zhuo J; Tan EH; Yan B; Tochhawng L; Jayapal M; Koh S; Tay HK; Maciver SK; Hooi SC; Salto-Tellez M; Kumar AP; Goh YC; Lim YC; Yap CT
PLoS One; 2012; 7(8):e43594. PubMed ID: 22927998
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma.
Weng CJ; Tsai CM; Chen YC; Hsieh YH; Lin CW; Liu YF; Su SC; Chen MK; Yang SF
Ann Surg Oncol; 2010 Dec; 17(12):3394-401. PubMed ID: 20706793
[TBL] [Abstract] [Full Text] [Related]
14. Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
Schrötzlmair F; Kopitz C; Halbgewachs B; Lu F; Algül H; Brünner N; Gänsbacher B; Krüger A
J Cell Mol Med; 2010 Dec; 14(12):2760-70. PubMed ID: 19863693
[TBL] [Abstract] [Full Text] [Related]
15. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract] [Full Text] [Related]
17. [Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2].
Mengele K; Harbeck N; Reuning U; Magdolen V; Schmitt M
Hamostaseologie; 2005 Aug; 25(3):301-10. PubMed ID: 16113755
[TBL] [Abstract] [Full Text] [Related]
18. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects.
Zhou XD
Hepatobiliary Pancreat Dis Int; 2002 Feb; 1(1):35-41. PubMed ID: 14607620
[TBL] [Abstract] [Full Text] [Related]
19. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer.
Seetoo DQ; Crowe PJ; Russell PJ; Yang JL
J Surg Oncol; 2003 Mar; 82(3):184-93. PubMed ID: 12619063
[TBL] [Abstract] [Full Text] [Related]
20. Cyclooxygenase-2 expression correlates with upaR levels and is responsible for poor prognosis of colorectal cancer.
Konno H; Baba M; Shoji T; Ohta M; Suzuki S; Nakamura S
Clin Exp Metastasis; 2002; 19(6):527-34. PubMed ID: 12405290
[TBL] [Abstract] [Full Text] [Related]
[Next]
